Diplomat Pharmacy (NYSE: DPLO) reported Q2 EPS of $0.23, $0.02 better than the analyst estimate of $0.21. Revenue for the quarter came in at $1.09 billion versus the consensus estimate of $1.12 billion.

GUIDANCE:

Diplomat Pharmacy sees FY2016 EPS of $0.90-$0.95, versus prior guidance of $0.88-$0.95 and the consensus of $0.93. Diplomat Pharmacy sees FY2016 revenue of $4.5-4.9 billion, versus the consensus of $4.76 billion.

For earnings history and earnings-related data on Diplomat Pharmacy (DPLO) click here.